What is LOPJLB’s current signal on ALGS?

LOPJLB’s latest quantitative signal on Aligos Therapeutics, Inc. (ALGS) is SELL in a RECOVERY regime. Signals are updated daily.

What market regime is ALGS in?

Aligos Therapeutics, Inc. (ALGS) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Aligos Therapeutics, Inc. (ALGS) do?

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset…

Where is Aligos Therapeutics, Inc. based / listed?

Aligos Therapeutics, Inc. is based in US, listed on NASDAQ.

Aligos Therapeutics, Inc. (ALGS)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$5.34+0.56%Close

SELLRECOVERY · day 10

[SCORES & PROFILE]

FUND: 5
VALUE: 1
GROWTH: 45
GARP: 5
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC-96.4%

REV YoY-

ROE-160.7%

EPS YoY-

ROA-114.5%

GROSS

-251

NET

-241

[VALUATION]

P/E TTM-0.74

P/E FWD-

SECTOR PE20.47

INDUSTRY PE13.95

P/B1.76

P/FCF-

EV/EBITDA-0.09

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E10.99

ALTMAN Z-

CURR RATIO2.19

ND/EBITDA-

BETA2.36

Aligos Therapeutics, Inc. (ALGS)

Key stats

Prediction markets

FUNDAMENTALS

Company news